Bulum Tomislav, Smircić-Duvnjak Lea, Car Nikica, Metelko Zeljko
Sveucilisna klinika za dijabetes, endokrinologiju i bolesti metabolizma Vuk Vrhovac, Medicinski fakultet Zagreb .
Lijec Vjesn. 2008 Jul-Aug;130(7-8):195-200.
Nowadays, diabetes affects about 200 million people worldwide, and represents the sixth-leading cause of death. Approximately 90 to 95% of those affected have type 2 diabetes, caused by two main mechanisms: insulin deficiency or peripheral insulin resistance. Early in the approach, diabetic patients are encouraged to make healthy lifestyle modifications including changes in diet, exercise patterns, and weight control. However, in most of patients, as the disease progresses, pharmacologic treatment becomes necessary. Despite the many pharmacological treatment modalities currently available, glucose control remains unsatisfactory in the type 2 diabetes population as evidenced by average hemoglobin A1c (HbA1c). The incretin mimetics and DPP-IV inhibitors are the new class of medications available for treating patients with diabetes type 2. The glycemic profiles of patients after administrations of incretin mimetics and DPP-IV inhibitors show improvement in postprandial glucose levels and ultimately in HbA1c. Therefore, incretin mimetics and DPP-IV inhibitors may play a clinically significant role in the treatment of patients with type 2 diabetes.
如今，糖尿病影响着全球约2亿人，是第六大致死原因。受影响者中约90%至95%患有2型糖尿病，其由两种主要机制引起：胰岛素缺乏或外周胰岛素抵抗。在治疗早期，鼓励糖尿病患者进行健康的生活方式改变，包括饮食、运动模式和体重控制方面的改变。然而，在大多数患者中，随着疾病进展，药物治疗变得必要。尽管目前有多种药物治疗方式，但从平均糖化血红蛋白（HbA1c）来看，2型糖尿病患者的血糖控制仍不尽人意。肠促胰岛素类似物和二肽基肽酶-4（DPP-IV）抑制剂是可用于治疗2型糖尿病患者的新型药物。给予肠促胰岛素类似物和DPP-IV抑制剂后，患者的血糖谱显示餐后血糖水平有所改善，最终糖化血红蛋白（HbA1c）也有所改善。因此，肠促胰岛素类似物和DPP-IV抑制剂可能在2型糖尿病患者的治疗中发挥重要的临床作用。
